GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » QHSLab Inc (OTCPK:USAQ) » Definitions » COGS-to-Revenue

QHSLab (QHSLab) COGS-to-Revenue : 0.42 (As of Mar. 2024)


View and export this data going back to 1990. Start your Free Trial

What is QHSLab COGS-to-Revenue?

QHSLab's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.20 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.49 Mil.

QHSLab's COGS to Revenue for the three months ended in Mar. 2024 was 0.42.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. QHSLab's Gross Margin % for the three months ended in Mar. 2024 was 58.49%.


QHSLab COGS-to-Revenue Historical Data

The historical data trend for QHSLab's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QHSLab COGS-to-Revenue Chart

QHSLab Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.60 0.53 0.50 0.44

QHSLab Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.44 0.43 0.40 0.42

QHSLab COGS-to-Revenue Calculation

QHSLab's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.615 / 1.409
=0.44

QHSLab's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.203 / 0.489
=0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


QHSLab  (OTCPK:USAQ) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

QHSLab's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.203 / 0.489
=58.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


QHSLab COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of QHSLab's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


QHSLab (QHSLab) Business Description

Traded in Other Exchanges
N/A
Address
901 Northpoint Parkway, Suite 302, West Palm Beach, FL, USA, 33407
QHSLab Inc is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. It is a medical device technology and software as a service (SaaS) company focused on enabling primary care physicians (PCPs) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease as well as provide preventive care through reimbursable procedures.
Executives
Troy James Grogan director, 10 percent owner, officer: CEO/Director 5480 N OCEAN DR B1D, SINGER ISLAND FL 33404
Richard J Rubin director, 10 percent owner, officer: CEO & Chairman 90 JOHN STREET, SUITE 626, NEW YORK NY 10038